CEO Chen Acquires 536,667 Shares in $5.55M PIPE, Boosting Stake to 49.76%
APLM has more than doubled off its 52-week low of $3.659.
Summary
CEO Hung-Wen Chen invested $5.55 million in Apollomics' private placement, acquiring 536,667 shares and raising his beneficial ownership to 49.76%.
Key Events · Ownership and Investor Activity · APLM
-
CEO Invests $5.55M in PIPE
Hung-Wen Chen acquired 370,000 shares for $5,550,005 in cash at $15.00 per share, plus 166,667 shares via conversion of his $2M note at $12.00 per share.
-
Ownership Rises to 49.76%
Chen's beneficial ownership increased to 1,453,029 shares, representing 49.76% of outstanding Class A shares, up from prior levels.
-
Waiver of $10M Threshold
Chen waived the $10 million minimum proceeds requirement, allowing the $8 million PIPE to trigger automatic conversion of his note.
-
Transaction Closed August 14
The private placement and note conversion closed on August 14, 2026, following subscription agreements signed August 7, 2026.
Analysis · APLM · Life Sciences
Chairman and CEO Hung-Wen Chen, directly and through his wholly-owned King Regent, acquired 536,667 Class A shares in the private placement that closed August 14, 2026. The purchase includes 370,000 shares for $5,550,005 in cash at $15.00 per share and 166,667 shares from conversion of his $2 million convertible note at $12.00 per share. Chen also waived the $10 million minimum proceeds threshold, allowing the $8 million PIPE to trigger the note conversion. His beneficial ownership now stands at 49.76% of outstanding shares, up from prior levels. This insider commitment is significant given the company's recent Nasdaq delisting scare and terminated licensing agreement.
How filings like this one have moved
In the 30 days to Sep 15, 2026, 29.9% of the 1678 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.25%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, APLM was trading at $23.55 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $51.7M. The 52-week trading range was $3.66 to $42.12. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.